Secondary Schizophrenia PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Secondary Schizophrenia PDF full book. Access full book title Secondary Schizophrenia by Perminder S. Sachdev. Download full books in PDF and EPUB format.
Author: Perminder S. Sachdev
Publisher: Cambridge University Press
ISBN: 1139485229
Category : Medical
Languages : en
Pages :
Get Book
Book Description
Schizophrenia may not be a single disease, but the result of a diverse set of related conditions. Modern neuroscience is beginning to reveal some of the genetic and environmental underpinnings of schizophrenia; however, an approach less well travelled is to examine the medical disorders that produce symptoms resembling schizophrenia. This book is the first major attempt to bring together the diseases that produce what has been termed 'secondary schizophrenia'. International experts from diverse backgrounds ask the questions: does this medical disorder, or drug, or condition cause psychosis? If yes, does it resemble schizophrenia? What mechanisms form the basis of this relationship? What implications does this understanding have for aetiology and treatment? The answers are a feast for clinicians and researchers of psychosis and schizophrenia. They mark the next step in trying to meet the most important challenge to modern neuroscience – understanding and conquering this most mysterious of human diseases.
Author: Perminder S. Sachdev
Publisher: Cambridge University Press
ISBN: 1139485229
Category : Medical
Languages : en
Pages :
Get Book
Book Description
Schizophrenia may not be a single disease, but the result of a diverse set of related conditions. Modern neuroscience is beginning to reveal some of the genetic and environmental underpinnings of schizophrenia; however, an approach less well travelled is to examine the medical disorders that produce symptoms resembling schizophrenia. This book is the first major attempt to bring together the diseases that produce what has been termed 'secondary schizophrenia'. International experts from diverse backgrounds ask the questions: does this medical disorder, or drug, or condition cause psychosis? If yes, does it resemble schizophrenia? What mechanisms form the basis of this relationship? What implications does this understanding have for aetiology and treatment? The answers are a feast for clinicians and researchers of psychosis and schizophrenia. They mark the next step in trying to meet the most important challenge to modern neuroscience – understanding and conquering this most mysterious of human diseases.
Author: Oliver Freudenreich
Publisher: Springer Nature
ISBN: 3030294501
Category : Medical
Languages : en
Pages : 479
Get Book
Book Description
This book provides clear and concise guidance for clinicians when they encounter a patient with psychosis, starting with the medical work-up to arrive at a diagnosis and ending with the comprehensive care for patients with established schizophrenia. It covers the optimal use of medications (emphasizing safe use) but also addresses other treatment approaches (psychological treatments, rehabilitation) and the larger societal context of care, including how to work effectively in complex systems. It uniquely condenses the literature into teaching points without simplifying too much, effectively serving as a learning tool for trainees and professionals. For this second edition, the book was extensively updated and its content expanded, with new figures as well. Each chapter begins with an initial summary and includes Tips and Key Points in text boxes. Each chapter also includes links to external websites and additional readings. The book contains clinical and practical wisdom for clinicians who are treating real patients at the front lines, setting it apart from all other texts. Psychotic Disorders is an excellent resource for medical students, early career professionals such as trainees and fellows, and related clinicians seeking additional training and resources, including those in psychiatry, psychology, neurology, and all others.
Author: Robin M. Murray
Publisher: Cambridge University Press
ISBN: 1139439480
Category : Medical
Languages : en
Pages : 474
Get Book
Book Description
An international team of leading researchers and clinicians here provide a comprehensive, epidemiological overview of this multi-faceted and still perplexing disorder, and address some of the key questions it raises. How important in the genetic contribution to schizophrenia? Do pregnancy and birth complications increase the risk for schizophrenia? Is the incidence of schizophrenia changing? Why is the rate higher among immigrants and in those born in cities? Controversial issues such as the validity of discrete or dimensional classifications of schizophrenia and the continuum between psychosis and 'normality' are explored in depth, and separate chapters are devoted to topics of particular relevance to schizophrenia such as suicide, violence and substance abuse. Finally, new prospects for treatment and prevention are considered. Drawing together the findings from social, genetic, developmental and classical epidemiology of schizophrenia, this text will prove an invaluable resource for clinicians and researchers.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9241547693
Category : Medical
Languages : en
Pages : 80
Get Book
Book Description
This manual attempts to provide simple, adequate and evidence-based information to health care professionals in primary health care especially in low- and middle-income countries to be able to provide pharmacological treatment to persons with mental disorders. The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalized anxiety and sleep disorders; obsessive compulsive disorders and panic attacks; and alcohol and opioid dependence. The annexes provide information on evidence retrieval, assessment and synthesis and the peer view process.
Author: Katherine J. Aitchison
Publisher: CRC Press
ISBN: 0429524145
Category : Medical
Languages : en
Pages : 152
Get Book
Book Description
The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management. This is an authoritative text written by a team of highly respected authors for psychiatrists, neurologists, primary care practitioners and health care professional working in psychiatry. Drawing from their experience, the presentation and assessment of the first psychotic episode are discussed, details regarding antipsychotic drugs and their appropriate use are reviewed and psychosocial approaches are examined. The resulting book offers a concise and valuable guide to those wishing to review the latest proposals for the treatment of first-episode psychosis supported by up-to-date references, in a single publication.
Author: Steven R. Hirsch
Publisher: John Wiley & Sons
ISBN: 1405140100
Category : Medical
Languages : en
Pages : 766
Get Book
Book Description
Schizophrenia is one of the most complex and puzzling diseases toaffect mankind. It is the most common of the severe mentalillnesses (psychoses) with an estimated prevalence of 0.5 - 1% inthe general population and accounts for a very large portion of theday to day workload of the average psychiatrist. 50% of long-termpsychiatric patients in mental hospitals are schizophrenic. There is a great deal of controversy about the causes, diagnosisand treatment of schizophrenia with the consequence that a hugeamount of research is carried out in the field by psychiatrists,psychologists, neuroscientists and pharmacologists. For the averagepractising psychiatrist seeing schizophrenics on a regular basis,making sense of the vast body of information on the subject andfiltering out what is of clinical relevance can be very difficult.There is a constant stream of new drugs emerging and the newergeneration of drugs (the so-called atypicals) is very effective,but often expensive. The Editors (one American and one British) are both highlyrespected clinical psychiatrists who are probably the leadingexperts on schizophrenia from their respective countries andjointly have published almost 150 papers on the subject. They have brought together a strong group of contributors from theUSA, UK and Europe to produce what will be an essential referencefor the trainee and practising psychiatrist. The book consists of four sections; descriptive aspects,causative aspects, physical treatments andpsychological/behavioural/social treatments. There will bediscussion of the theoretical controversies over symptomatology,classification and aetiology, the relationship of schizophrenia tothe other psychoses, the significance of positive and negativesymptoms and pre-morbid personality. There will be chapters onorganic models of schiziophrenia, neurodevelopmental, genetic andstructural studies and the role of high-expressed emotion. Thefinal section will cover social and environmental treatment, therole of the families of schizophrenics and the psychoanalyticaltherapies. There is a new chapter on the patient's perspectivewritten by a former patient.
Author: U. S. Department of Health and Human Services
Publisher: Createspace Independent Pub
ISBN: 9781483944234
Category : Medical
Languages : en
Pages : 570
Get Book
Book Description
Antipsychotic medications are used to treat and manage symptoms for several psychiatric disorders and are commonly categorized into two classes. First-generation antipsychotics (FGAs), also known as “typical antipsychotics,” were developed in the 1950s. Second-generation antipsychotics (SGAs), also known as “atypical antipsychotics,” emerged in the 1980s. To date, FGAs have been classified according to their chemical structure, which includes serotonin-dopamine antagonists and multiacting receptor-targeted antipsychotics, whereas SGAs have been categorized according to their pharmacological properties as dopamine partial agonists. There is ongoing research testing the proposed mechanisms of action within each class with respect to the neurobiology of different psychiatric disorders. According to findings from the 2004–05 Medical Expenditure Panel Survey, an estimated 2 million adult patients in the U.S. were prescribed an antipsychotic medication, three quarters of whom were taking an SGA. In 2003, an estimated $2.82 billion were spent in the country on these medications, with SGAs accounting for 93% of this expenditure. Today, 20 FGAs and SGAs are commercially available in the U.S. and approved by the FDA. Individuals taking antipsychotics may stop taking their medication for a number of reasons, including adverse events (AEs) and a lack of improvement in their symptoms. As a result, ongoing evaluations of drug efficacy and models of patient decisionmaking are essential. This Review provides a comprehensive synthesis of the evidence examining the benefits and harms associated with the use of FDA-approved FGAs and SGAs. This CER focuses on comparisons of individual medications rather than drug classes. This topic is important and timely, given the ongoing debate about the comparative benefits and harms of FGAs and SGAs. The focus of this report complements other recent reviews investigating different SGAs, the off-label use of antipsychotics, and FGAs versus SGAs in the pediatric population. The focus of this report is adults age 18 to 64 years with schizophrenia, schizophrenia-related psychoses, and bipolar disorder. The following Key Questions were investigated in the report: 1. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, what are the comparative efficacy and effectiveness of FGAs versus SGAs for improving core illness symptoms? 2. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, what is the comparative effectiveness of FGAs versus SGAs for improving functional outcomes and decreasing health care system utilization? 3. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, do FGAs and SGAs differ in medication-associated AEs and safety? 4. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, what is the comparative effectiveness of FGAs versus SGAs for the following other outcomes: Relapse and remission rates, Medication adherence and persistent use, Patient insight into illness, Health-related quality of life, Patient satisfaction, Comorbidity: endpoints of victimization, homelessness, and substance abuse, Patient-reported outcomes, Ability to obtain and retain employment and succeed in job duties, Concomitant use of other medications, especially those used to treat EPS, and Patient preferences. 5. For adults (age 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, what are the comparative effectiveness and risks of FGAs versus SGAs in subgroups defined by the following variables? Disorder subtypes, Sex, Age group (18–35 years, 36–54 years, and 55–64 years), Race, Comorbidities, Drug dosage, Follow up period, Treatment of a first episode versus treatment in the context of previous episodes (previous exposure to antipsychotics), and Treatment resistance.
Author: Michael Poyurovsky
Publisher: Cambridge University Press
ISBN: 1107000122
Category : Medical
Languages : en
Pages : 249
Get Book
Book Description
This is the first book to address the clinical and neurobiological interface between schizophrenia and obsessive-compulsive disorder (OCD). There is growing evidence that obsessive-compulsive symptoms in schizophrenia are prevalent, persistent and characterized by a distinct pattern of familial inheritance, neurocognitive deficits and brain activation. This text provides guidelines for differential diagnosis of schizophrenic patients with obsessive-compulsive symptoms, and patients with primary OCD alongside poor insight, psychotic features or schizotypal personality. Written by a leading expert in the coexistence of obsessive-compulsive and schizophrenic phenomena, Schizo-Obsessive Disorder uses numerous case studies to present diagnostic guidelines and to describe a recommended treatment algorithm, demystifying this complex disorder and aiding its effective management. The book is essential reading for psychiatrists, neurologists and the wider range of multidisciplinary mental health practitioners.
Author: Robert E. Hales
Publisher: American Psychiatric Pub
ISBN: 1585622575
Category : Medical
Languages : en
Pages : 1820
Get Book
Book Description
Its previous edition hailed as "the best reference for the majority of practicing psychiatrists" (Doody's Book Reviews) and a book that "more than any other, provides an approach to how to think about psychiatry that integrates both the biological and psychological" (JAMA), The American Psychiatric Publishing Textbook of Psychiatry has been meticulously revised to maintain this preeminence as an accessible and authoritative educational reference and clinical compendium. It combines the strengths of its three editors -- Robert Hales in clinical and community psychiatry, Stuart Yudofsky in neuropsychiatry, and new co-editor Glen Gabbard in psychotherapy -- in recruiting outstanding authors to summarize the latest developments in psychiatry and features 101 contributors, 65 of whom are new to this edition. The book boasts a new interior design, with more figures and color throughout to aid comprehension. Each chapter ends with 5-10 key points, 5-10 recommended readings, and helpful Web sites not only for the clinician but also for patients and family members. The book also includes complimentary access to the full text online. Online benefits include powerful searching, electronic bookmarking, and access by username and password from wherever you have Web access -- especially convenient for times when the print copy of your textbook is not where you are. The online version is accompanied by a downloadable PowerPoint presentation, which contains a wealth of material to enhance classroom presentation, study, and clinical use. Among the improvements to this edition's content: • Of the text's 44 chapters, 23 either feature new topics or have new authors, making this the most completely revised edition yet.• New basic-science chapters on cellular and molecular biology of the neuron and on neuroanatomy for the psychiatrist conveniently distill essential information on the biological foundations of psychiatric disorders for clinicians.• A new chapter on human sexuality and sexual dysfunctions, and another new chapter on treatment of gay, lesbian, bisexual, and transgender patients, equips clinicians to address the entire spectrum of sexual issues and their attendant mental health concerns.• New chapters on nonpharmacological somatic treatments, supportive psychotherapy, and combination psychotherapy and pharmacotherapy augment the section on psychiatric treatments.• A new chapter on the assessment of dangerousness -- an individual's propensity to commit violent acts -- presents helpful guidelines for appropriately evaluating and minimizing the risk of violence in both outpatient and inpatient settings. Why The American Psychiatric Publishing Textbook of Psychiatry will be your first choice among comprehensive psychiatry textbooks: • Complimentary Access to the Full Text Online -- Online benefits include powerful searching, electronic bookmarking, and download to PDA.• PowerPoint Presentation -- Online version is accompanied by a downloadable PowerPoint presentation, which contains a wealth of material to help you enhance classroom presentation, study, and in clinical use. • Self-Assessment -- An interactive online Self-Assessment allows you to assess your knowledge of each chapter, with links back to the textbook when more study is needed.• Summary Points -- Each chapter ends with 5-10 key points, 5-10 recommended readings, and helpful web sites not only for the clinician but also for referral to patients and family members. • Co-Editor Glen O. Gabbard, M.D. -- As the third Co-Editor, Dr. Gabbard adds depth and perspective to psychotherapeutic approaches.• Chapter Authors -- Partnership of senior and junior faculty brings fresh insights tempered by wisdom and experience.• Peer-Reviewed -- Rigorously peer reviewed and updated to reflect the rapidly changing profession. • Disclosure of Interest Statements -- Disclosure from each chapter author assures you that potential biases have been removed.• Comprehensive But Concise -- Inclusion of essential information eases information overload.• Better Layout -- Larger type for text makes book easier to read and color figures are provided throughout the text. It's no wonder that this text has established itself as both a leading scholarly reference and an indispensable clinical resource. The American Psychiatric Publishing Textbook of Psychiatry is a proven teaching tool and an essential component of every practitioner's library.
Author: Richard S. E. Keefe
Publisher: American Psychiatric Pub
ISBN: 1585627976
Category : Medical
Languages : en
Pages : 216
Get Book
Book Description
For the first time in a single volume, distinguished experts address the complex issues -- issues rarely confronted in empirical studies of patients with schizophrenia -- and controversial research surrounding the assessment of negative symptoms and cognitive deficits in patients with schizophrenia. Despite recent advances in our understanding of schizophrenia, still notably absent is consensus in assessing negative symptom treatment response. What is the most effective assessment method -- given the varying methodologies and contradictory results to date? What constitutes an adequate response? Which medication -- none is specifically indicated and licensed for negative symptom treatment -- yields the best results? What are the indications for use of this medication? Which instrument best measures negative symptom treatment response (eight rating scales are analyzed here)? Reaching consensus among clinicians and researchers alike is even more difficult because assessment is often thwarted by extrapyramidal side effects of medications, similarities to depressive symptoms, and secondary effects of psychotic experiences. In addition to clarifying these pressing issues, Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia also discusses The importance of measuring the experience of emotion versus the more traditional objectively measured symptoms in patients with schizophrenia, and how deficits in emotional experience may resist treatment -- even in treatment-responsive patients. The family as an often overlooked source of information about negative symptom improvement or worsening, and the impact of negative symptoms on patients' relatives. How treatment affects social functioning and subjective experience of "quality of life," and the importance of neurocognitive dysfunction in the social deficits of schizophrenia, which often persist despite significant amelioration of other symptoms. Specific guidelines for assessing neurocognitive treatment response. Cognitive enhancement is a major factor in improving the quality of patients' lives. The latest research on the neurobiology of negative symptoms, including the role of various neurotransmitter systems and brain regions in mediating negative symptom pathology. Also discussed is single vs. multiple pathophysiological processes and single treatment modality vs. distinct treatments for different aspects of negative symptoms. How to distinguish "pure" negative symptoms from deficit symptoms (i.e., those that persist for at least 1 year and are not secondary to factors such as depression, medication side effects, anxiety, delusions, and hallucinations), and which treatment is indicated for each. Highlighted by patient vignettes, this in-depth guide will be welcomed by all clinicians who treat patients with schizophrenia and want to know and document whether their interventions ameliorate negative symptoms and cognitive dysfunction, and by all researchers who study schizophrenia, particularly those interested in clinical issues and treatment studies.
